We do, however, acknowledge that the current study was not designed to explore such later metabolic perturbations, and current knowledge supports the concept that multiple factors are involved in the development of hypogonadal metabolic dysfunction (50). This, in turn, provides one potential mechanism by which hypogonadal insulin resistance may ensue over time. Since clearance is a composite parameter, these data do not provide detailed information on tissue-specific clearance. However, no data exist describing the molecular regulation of secretion pattern by T, but we speculate that T can elicit cAMP and PKA activation through the SHBG receptor in the plasma membrane (43). It has been observed with other incubation protocols that differentiated human pre-adipocytes and mature human cells from both regions express androgen receptors 27, 28. However, our findings could explain why in humans treated with testosterone the volume of visceral adipose tissue and triglyceride accumulation in this adipose region was selectively reduced 25, 26. It is possible that enhanced lipid synthesis and not lipolytic activity is the major factor behind expansion of visceral adipose tissue. We have previously shown that lipolysis induced by noradrenaline is faster in differentiated pre-adipocytes from the omental than in similar pre-adipocytes from the abdominal subcutaneous adipose depot . Our results for testosterone and lipolysis are different from those reported in several rodent studies. The inhibitory effect of testosterone in subcutaneous cells was as marked in men as in women. Effect of different concentrations of testosterone (0, 0.01, 0.1, 1 µmol/l). Additional experiments showed that flutamide alone had no effect on lipolysis. The inhibitory effect on catecholamine-induced lipolysis was concentration-dependent (pp5). C, control; T, testosterone-treated; GPDH, glycerol-3-phosphate dehydrogenase Basal lipolysis and lipolysis stimulated with 0.1 mmol/l adrenaline (Adr), adrenaline plus 0.1 mmol/l yohimbine (Yoh) and 10 µmol/l isoprenaline (Iso) were investigated. More importantly, it had no effect on any lipolytic criterion in pre-adipocytes from the omental region (Fig. 2). However, to correct lipolysis for small variations in cell loading and degree of differentiation, glycerol release was related to GPDH activity. Indeed, SREBP-1 null mice display impaired up-regulation of lipogenic gene expression on a fasting/refeeding protocol (Shimano et al., 1999). When levels of free cholesterol in the cell are high, SREBP-2 is present as a large immature precursor bound to the endoplasmic reticulum. It probably binds to some kind of cell surface receptor, thereby activating a signaling cascade that involves phosphodiesterase 3 (Van Harmelen et al., 1999). A final endocrine/autocrine factor connected with triglyceride synthesis is acylation stimulating protein (ASP). Interestingly, another negative target of leptin is probably SREBP-1, suggesting that this transcription factor may be involved in mediating the inhibitory effect of leptin on lipogenic gene expression (Kakuma et al., 2000; Soukas et al., 2000). Another hormone that has an important influence on lipogenesis is growth hormone (GH). Respond more robustly to this signaling than subcutaneous fat. This triggers cyclic AMP (cAMP) accumulation, activating protein kinase A (PKA), which phosphorylates transcription factors that upregulate GH gene expression. Real Peptides supplies Tesamorelin Peptide synthesized through exact amino-acid sequencing for research applications examining GHRH receptor dynamics and fat depot selectivity. Effect of testosterone treatment on lipolysis in subcutaneous pre-adipocytes. These cells maintain the lipolytic phenotype of adult mature fat cells i.e. a high catecholamine-induced rate of lipolysis in the omental region and a low rate in the subcutaneous region . In contrast, testosterone had no effect on lipolysis or protein expression in the visceral depot. Abnormalities of AT lipolysis causes excess FFA, which can result in hepatic and muscle insulin resistance, increased very low-density lipoprotein-triglyceride-level production, abnormal vascular constriction, and excess insulin secretion. For example, these hormones could alter FFA release from visceral depot and this would not be reflected in our measures of systemic lipolysis. As mentioned above, VLDL is the main form for transporting endogenous TG, while low-density lipoprotein (LDL) mainly transports endogenous cholesterol. Phospholipids and their derived components are the basic components of biological membranes. Cyclization of adenylate further activates cAMP-dependent protein kinase and increases adipose triglyceride lipase (ATGL) activity. Hormones like adrenaline, norepinephrine, and glucagon triggered by fasting, starvation and sympathetic excitement stimulate fat mobilization. This assumption is confirmed by the observation that men with type 1 diabetes with a high BMI show lower levels of testosterone. This difference was attributed to the differences in circulating levels of insulin (low in type 1 and high in type 2). Interestingly, there is a significant difference in plasma testosterone levels between men with diabetes type 1 (who have normal levels) and type 2 (who have subnormal levels) . In addition, insulin probably increases transcriptional activation by SREBP-1, independently of changes in its mRNA levels, via MAP-kinase-dependent phosphorylation (Roth et al., 2000). Overall, these data suggest that the roles of SREBP-1 in liver and adipose tissue may differ. An even more striking and counterintuitive observation in these mice was that their adipose tissue mass was reduced to less than half that of wild-type mice. Surprisingly, the phenotype of SREBP-1 null mice revealed that SREBP-1 probably has a somewhat different role in adipose tissue. Interestingly, in mice that overexpress SREBP-1a or SREBP-1c in liver, a dramatic build-up of hepatic triglycerides and elevated expression levels of lipogenic genes were observed.
